Protea buys CRO vivoPharm for preclinical expertise

West Virginia bioanalytics outfit Protea Biosciences has acquired preclinical researcher vivoPharm to expand in the world of early-stage oncology development. VivoPharm specializes in crafting tumor models and cell lines for cancer research, working with pharma and biotech on preclinical studies. Protea, which focuses on molecular information and R&D imaging, believes combining the two companies will create a unique presence on the market. Release